| Excerpt | Relevance | Reference |
|---|
| " For this reason, in a series of preclinical studies, we tested the potential of a recently developed small-molecule inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)." | 7.75 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. ( Acevedo, LM; Cheresh, DA; Dellamary, L; Dneprovskaia, E; Doukas, J; Eide, L; Martin, M; Noronha, G; Racanelli-Layton, A; Soll, R; Stebbins, K; Wrasidlo, W, 2009) |
| " For this reason, in a series of preclinical studies, we tested the potential of a recently developed small-molecule inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)." | 3.75 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. ( Acevedo, LM; Cheresh, DA; Dellamary, L; Dneprovskaia, E; Doukas, J; Eide, L; Martin, M; Noronha, G; Racanelli-Layton, A; Soll, R; Stebbins, K; Wrasidlo, W, 2009) |